Heron Therapeutics (HRTX) Gross Margin: 2010-2025
Historic Gross Margin for Heron Therapeutics (HRTX) over the last 11 years, with Sep 2025 value amounting to 68.82%.
- Heron Therapeutics' Gross Margin fell 235.00% to 68.82% in Q3 2025 from the same period last year, while for Sep 2025 it was 73.92%, marking a year-over-year increase of 173.00%. This contributed to the annual value of 73.21% for FY2024, which is 2446.00% up from last year.
- As of Q3 2025, Heron Therapeutics' Gross Margin stood at 68.82%, which was down 6.37% from 73.50% recorded in Q2 2025.
- In the past 5 years, Heron Therapeutics' Gross Margin ranged from a high of 78.26% in Q1 2025 and a low of -18.55% during Q4 2021.
- Its 3-year average for Gross Margin is 64.18%, with a median of 71.12% in 2023.
- Per our database at Business Quant, Heron Therapeutics' Gross Margin crashed by 7,297bps in 2021 and then skyrocketed by 7,650bps in 2022.
- Over the past 5 years, Heron Therapeutics' Gross Margin (Quarterly) stood at -18.55% in 2021, then skyrocketed by 7,650bps to 57.95% in 2022, then skyrocketed by 1,318bps to 71.12% in 2023, then soared by 380bps to 74.92% in 2024, then tumbled by 235bps to 68.82% in 2025.
- Its last three reported values are 68.82% in Q3 2025, 73.50% for Q2 2025, and 78.26% during Q1 2025.